Press Release Details

Cerus Corporation Appoints Chief Financial Officer

May, 07 1999

CONCORD, Calif., May 7 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS), a leading developer of systems to inactivate pathogens in transfused blood components, announced today the appointment of Gregory W. Schafer as Vice President of Finance and Chief Financial Officer. Mr. Schafer has served as the company's Director of Finance since 1997. In that capacity, Mr. Schafer was responsible for financial reporting, SEC compliance, planning and budgeting, investor relations and corporate communications. Mr. Schafer replaces Robert Miller, who has resigned to pursue other interests.

Prior to joining Cerus, Mr. Schafer was a management consultant with Deloitte & Touche LLP with a focus in operations and financial consulting to the high technology industry. Mr. Schafer holds an MBA from the Anderson School at UCLA and a BSE in Mechanical Engineering from the University of Pennsylvania.

"I am confident that Greg's experience, knowledge of our industry and demonstrated performance will serve Cerus well," said Cerus President and Chief Executive Officer Stephen Isaacs. "As we move through clinical development toward commercialization, Greg's skills and background will be instrumental to our growth."

Cerus Corporation is developing systems designed to enhance the safety of blood transfusions by inactivating pathogens in blood components (platelets, plasma and red blood cells used for transfusion) and by inactivating white blood cells, which are responsible for a variety of adverse transfusion reactions. The company's platform technologies, which prevent viral, bacterial and cellular replication, may have potential applications in the health care field beyond pathogen inactivation in blood components.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any trials, regulation by the FDA, the uncertainty of replication of animal data in humans, the uncertainty of market acceptance of any products, competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1998 Annual Report on Form 10-K.

CONTACT: Stephen Isaacs, President and CEO, or Gregory W. Schafer, CFO,

both of Cerus Corporation, 925-603-9071; or Ana Kapor,

investors, or Amy Flood, media, both of Noonan/Russo

Communications, Inc. 415-677-4455 for Cerus Corporation.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600